
Quarterly report 2025-Q3
added 11-06-2025
BioLife Solutions EBITDA 2011-2026 | BLFS
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA BioLife Solutions
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.97 M | -16.3 M | 852 K | -30.5 M | -4.21 M | 1.85 M | 4 M | -717 K | -4.48 M | -3.04 B | -2.88 M | -38.3 K | -773 K | -1.11 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4 M | -3.04 B | -221 M |
Quarterly EBITDA BioLife Solutions
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 111 K | -16.4 M | -536 K | - | -218 K | -1.11 M | -1.93 M | - | -14.5 M | -9.83 M | -11.9 M | - | -10.8 M | -75.9 M | -6.31 M | - | -8.12 M | -2.66 M | -204 K | - | 208 K | 1.02 M | 783 K | - | -399 K | 956 K | 664 K | - | 1.44 M | 1.45 M | 218 K | - | 228 K | -165 K | -374 K | - | -862 K | -1.41 M | -1.4 M | - | -1.04 M | -987 K | -1.08 M | - | -688 K | -765 K | -307 K | - | 73.2 K | 35.4 K | 251 K | - | -38.7 K | -247 K | -153 K | - | -214 K | -214 K | -431 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.45 M | -75.9 M | -3.64 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical instruments industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Merit Medical Systems
MMSI
|
308 M | $ 67.55 | -0.85 % | $ 4 B | ||
|
ICU Medical
ICUI
|
244 M | $ 129.4 | -0.41 % | $ 3.19 B | ||
|
Luminex Corporation
LMNX
|
72.9 M | - | - | $ 1.75 B | ||
|
Envista Holdings Corporation
NVST
|
332 M | $ 26.03 | 0.81 % | $ 4.37 B | ||
|
Akers Biosciences, Inc.
AKER
|
-12.3 M | - | -9.52 % | $ 20.6 M | ||
|
Atrion Corporation
ATRI
|
37.7 K | - | - | $ 810 M | ||
|
Ekso Bionics Holdings
EKSO
|
-11.8 M | $ 10.5 | -0.94 % | $ 25.5 M | ||
|
Antares Pharma, Inc.
ATRS
|
16.2 M | - | - | $ 955 M | ||
|
Pro-Dex
PDEX
|
11.9 M | $ 49.99 | 4.25 % | $ 164 M | ||
|
Cantel Medical Corp.
CMD
|
123 M | - | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
33.9 M | - | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
518 M | - | -0.05 % | $ 10.3 B | ||
|
Pulse Biosciences
PLSE
|
-76.5 M | $ 21.29 | 1.72 % | $ 1.43 B | ||
|
Varian Medical Systems, Inc.
VAR
|
60 M | - | -0.02 % | $ 16.3 B | ||
|
Nephros
NEPH
|
-1.38 M | $ 3.05 | -1.93 % | $ 31.7 M | ||
|
Haemonetics Corporation
HAE
|
337 M | $ 56.66 | -3.08 % | $ 2.85 B | ||
|
Baxter International
BAX
|
673 M | $ 16.72 | 0.57 % | $ 8.58 B | ||
|
OraSure Technologies
OSUR
|
-61.8 M | $ 3.06 | -0.65 % | $ 225 M | ||
|
Isoray
ISR
|
-110 M | - | 0.03 % | $ 108 M | ||
|
AngioDynamics
ANGO
|
-14.2 M | $ 10.63 | -0.75 % | $ 434 M | ||
|
Intuitive Surgical
ISRG
|
3.55 B | $ 471.91 | -1.28 % | $ 168 B | ||
|
Repligen Corporation
RGEN
|
116 M | $ 116.3 | -0.04 % | $ 6.48 M | ||
|
AtriCure
ATRC
|
2.64 M | $ 29.61 | -0.57 % | $ 1.41 B | ||
|
InfuSystem Holdings
INFU
|
15 M | $ 9.69 | 0.94 % | $ 200 M | ||
|
iRhythm Technologies
IRTC
|
-36.7 M | $ 118.69 | 0.47 % | $ 3.8 B | ||
|
Milestone Scientific
MLSS
|
-6.72 M | $ 0.29 | 3.78 % | $ 23.1 M | ||
|
electroCore
ECOR
|
-12.7 M | $ 6.17 | 0.65 % | $ 52.3 K | ||
|
STERIS plc
STE
|
1.34 B | $ 221.73 | 0.33 % | $ 21.9 B | ||
|
Stereotaxis
STXS
|
-21.5 M | $ 1.8 | -2.17 % | $ 164 M | ||
|
Teleflex Incorporated
TFX
|
192 M | $ 106.56 | 0.67 % | $ 4.75 B | ||
|
Predictive Oncology
POAI
|
-10.8 M | - | - | $ 31.1 M | ||
|
Glaukos Corporation
GKOS
|
-95 M | $ 105.23 | -1.51 % | $ 5.1 B | ||
|
Utah Medical Products
UTMD
|
17.4 M | $ 63.8 | -2.04 % | $ 232 M | ||
|
ResMed
RMD
|
1.16 B | $ 228.19 | 0.1 % | $ 33.3 B | ||
|
Microbot Medical
MBOT
|
-9.75 M | $ 2.5 | -0.79 % | $ 25.5 M | ||
|
West Pharmaceutical Services
WST
|
756 M | $ 245.27 | 1.6 % | $ 17.7 B | ||
|
Retractable Technologies
RVP
|
-13.5 M | $ 0.72 | -0.04 % | $ 21.6 M | ||
|
DENTSPLY SIRONA
XRAY
|
-70 M | $ 11.47 | -0.65 % | $ 2.29 B | ||
|
NeuroMetrix
NURO
|
-8.69 M | - | 5.05 % | $ 9.02 M | ||
|
The Cooper Companies
COO
|
1.06 B | $ 70.49 | 0.36 % | $ 14 B | ||
|
STAAR Surgical Company
STAA
|
-83.4 M | $ 18.97 | 2.49 % | $ 940 M | ||
|
Harvard Bioscience
HBIO
|
-46.8 M | $ 5.13 | -3.93 % | $ 228 M | ||
|
Becton, Dickinson and Company
BDX
|
5.04 B | $ 155.92 | -0.19 % | $ 44.9 B | ||
|
Repro Med Systems
KRMD
|
-2.16 M | $ 4.4 | -0.68 % | $ 203 M | ||
|
LeMaitre Vascular
LMAT
|
78.3 M | $ 109.99 | 1.97 % | $ 2.49 B | ||
|
Masimo Corporation
MASI
|
-164 M | $ 178.69 | 0.14 % | $ 9.52 B | ||
|
Alcon
ALC
|
580 M | $ 74.24 | 0.13 % | $ 40.4 B |